[Ip-health] KEI statement regarding Gilead's Acquisition of Kite Pharma

Kim Treanor kim.treanor at keionline.org
Mon Aug 28 08:54:17 PDT 2017

KEI statement regarding Gilead’s Acquisition of Kite Pharma.

“Congress should require the NIH to enforce the Bayh-Dole obligation to
make the Kite Pharma Chimeric Antigen Receptors Technologies (CAR T)
treatments available to the public on reasonable terms.

KEI notes that Kite reported spending $317 million in R&D from 2012 to June
30, 2017, and is selling the company for $11.9 billion.

The NIH should explain (1) why it told the New York Times that it would
ignore the Bayh-Dole requirements on reasonable pricing in 2016, (2)
whether or not this statement drove up the price for Gilead to acquire
Kite, and (3) when Gilead cites the high cost of the acquisition to justify
high prices for the treatment, whether the NIH policy needs to change.

The NIH should provide details of the royalties it has received from Kite,
and the details of the royalty payments to the NIH going forward.

KEI will also ask Gilead to license all of the patents held by Kite to the
Medicines Patent Pool to expand access in developing countries.”

James Love, Director, KEI

For more information, contact: Kim Treanor kim.treanor at keionline.org or


Kim Treanor
Knowledge Ecology International
kim.treanor at keionline.org
tel.: +1.202.332.2670

More information about the Ip-health mailing list